The study aims to use 'omics' sciences, employing the most advanced technologies currently available, in order to identify pathogenic genomic variants, proteins and/or altered molecular pathways in neurodegenerative diseases and to obtain a new and more complete characterisation of subjects affected by the neurodegenerative diseases under study. Thanks to the integration of genomic, gene expression (transcriptomic and epigenomic), protein and metabolic data and clinical data, the study also aims to identify new markers for the diagnosis, prognosis, also in terms of response to therapy, and monitoring of neurodegenerative diseases.
The study involves the enrolment of at least 1.200 individuals with neurodegenerative disease.
None
None
NeurOmics is a multicenter observational study, conducted on patients diagnosed with neurodegenerative disease (AD, MCI, PD, ALS, atypical parkinsonisms)
Cohort
Prospective
Not listed
Identify variants in our genetic makeup, proteins, and/or altered metabolic pathways in patients with neurodegenerative diseases
Thanks to the integration of genomic, gene expression, protein and metabolic data and clinical data, the Firm aims to identify new markers for diagnosis, prognosis, also in terms of response to therapy, and monitoring of neurodegenerative diseases. There will be three outcomes from the study. * Identification of variants in our coding DNA (i.e. that serves to produce proteins needed by our cells) that are known to cause or predispose to Alzheimer's disease; * Analyze the non-coding regions of our DNA (i.e. regions that serve to regulate, modify, inhibit the production of proteins in our body) in search of variants that can cause, modify the prognosis and/or response to drugs in Alzheimer's disease; * Investigate the role of genetic-molecular alterations on the clinical phenotype for the most frequent variants
Click on the lead sponsor to view all of their trials.
Ospedale Policlinico San Martino
Lead sponsor
Istituto Italiano di Tecnologia
Collaborator
